Kandu Health announced positive results from the first randomized controlled trial of its brain-computer interface (BCI) therapy. The trial evaluated its FDA-cleared, non-invasive IpsiHand BCI system in chronic stroke survivors. It detailed outcomes from a post-market randomized controlled study evaluating the clinical performance of IpsiHand. IpsiHand received FDA clearance in 2021 as a breakthrough-designated, 510(k)-cleared device for stroke rehabilitation.
